{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T14:17:08Z","timestamp":1784125028536,"version":"3.55.0"},"reference-count":7,"publisher":"PAGEPress Publications","license":[{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dermatol Reports"],"abstract":"<jats:p>Atopic dermatitis (AD) and hidradenitis suppurativa (HS) are two common chronic inflammatory skin diseases associated with a significant impairment of patients\u2019 quality of life. Although AD and HS are substantially different from a pathogenetic perspective, recent findings have indicated the existence of potential common pathogenetic mechanisms, including skin barrier alteration. We describe a 29-year-old male with concomitant HS and AD who obtained a marked improvement of both diseases under treatment with dupilumab, a monoclonal antibody that inhibits interleukin (IL)-4\/IL-13 signaling. This finding supports the hypothesis that type 2 inflammation and skin barrier dysfunction play a significant role in the pathogenesis of HS.<\/jats:p>","DOI":"10.4081\/dr.2026.10292","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T14:00:51Z","timestamp":1784124051000},"source":"Crossref","is-referenced-by-count":0,"title":["Hidradenitis suppurativa characterized by type 2-skewed inflammatory features when associated with atopic dermatitis: critical appraisal of a dupilumab-treated case report"],"prefix":"10.4081","author":[{"given":"Niccol\u00f2","family":"Gori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Ippoliti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flaminia","family":"Antonelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludovica","family":"Manieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ketty","family":"Peris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2549","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"key":"41945","doi-asserted-by":"crossref","unstructured":"1. Kaakati RN, Tanaka J, Liu B, et al. Atopic dermatitis is associated with hidradenitis suppurativa diagnosis: A single-institution retrospective cohort study. JAAD Int 2021;4:18-24.","DOI":"10.1016\/j.jdin.2021.04.006"},{"key":"41946","doi-asserted-by":"crossref","unstructured":"2. Sherman S, Kridin K, Bitan DT, et al. Hidradenitis suppurativa and atopic dermatitis: A 2-way association. J Am Acad Dermatol 2021;85:1473-9.","DOI":"10.1016\/j.jaad.2020.12.051"},{"key":"41947","doi-asserted-by":"crossref","unstructured":"3. Dany M, Elston D. Gene expression of sphingolipid metabolism pathways is altered in hidradenitis suppurativa. J Am Acad Dermatol 2017;77:268-73.e6.","DOI":"10.1016\/j.jaad.2017.03.016"},{"key":"41948","doi-asserted-by":"crossref","unstructured":"4. Berdyshev E, Goleva E, Bissonnette R, et al. Dupilumab significantly improves skin barrier function in patients with moderate-to-severe atopic dermatitis. Allergy 2022;77:3388-97.","DOI":"10.1111\/all.15432"},{"key":"41949","doi-asserted-by":"crossref","unstructured":"5. Cho MK, Shin JU, Kim DH, Lee HJ. Severe atopic dermatitis and concurrent severe hidradenitis suppurativa successfully treated with dupilumab. Clin Exp Dermatol 2022;47:2303-5.","DOI":"10.1111\/ced.15387"},{"key":"41950","doi-asserted-by":"crossref","unstructured":"6. Molinelli E, Sapigni C, Simonetti O, et al. Successfully and safety use of dupilumab in the management of severe atopic dermatitis and concomitant moderate-to-severe hidradenitis suppurativa. Dermatol Ther 2022;35:e15645.","DOI":"10.1111\/dth.15645"},{"key":"41951","doi-asserted-by":"crossref","unstructured":"7. Gambardella A, Calabrese G, Di Brizzi EV, et al. A case of atopic dermatitis and Hidradenitis Suppurativa successfully treated with Dupilumab. J Eur Acad Dermatol Venereol 2020;34:e284-6.","DOI":"10.1111\/jdv.16280"}],"container-title":["Dermatology Reports"],"original-title":[],"link":[{"URL":"https:\/\/journals.pagepress.net\/dr\/article\/download\/10292\/9982","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.pagepress.net\/dr\/article\/download\/10292\/9982","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T14:00:56Z","timestamp":1784124056000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.pagepress.net\/dr\/article\/view\/10292"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":7,"URL":"https:\/\/doi.org\/10.4081\/dr.2026.10292","relation":{},"ISSN":["2036-7406","2036-7392"],"issn-type":[{"value":"2036-7406","type":"electronic"},{"value":"2036-7392","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,15]]}}}